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Regular Article
PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
cIAPs and XIAP regulate myelopoiesis through cytokine production in
an RIPK1- and RIPK3-dependent manner
W. Wei-Lynn Wong,1-3 James E. Vince,1,2 Najoua Lalaoui,1,2 Kate E. Lawlor,1,2 Diep Chau,1 Aleksandra Bankovacki,1
Holly Anderton,1 Donald Metcalf,1,2 Lorraine O’Reilly,1,2 Philipp J. Jost,1 James M. Murphy,1,2 Warren S. Alexander,1,2
Andreas Strasser,1,2 David L. Vaux,1,2 and John Silke1-3
1The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; 2Department of Medical Biology, University of Melbourne, Parkville, VIC,
Australia; and 3Department of Biochemistry, La Trobe University, Bundoora, VIC, Australia
Key Points
• cIAPs and XIAP negatively
regulate cytokine production,
including TNF to disrupt
myeloid lineage differentiation.
• IAPs prevent RIPK1 and
RIPK3 activity to limit cytokine
production prior to cell death.
Lossof inhibitor of apoptosisproteins (IAPs), particularly cIAP1, canpromoteproduction
of tumor necrosis factor (TNF) and sensitize cancer cell lines to TNF-inducednecroptosis
by promoting formation of a death-inducing signaling complex containing receptor-
interacting serine/threonine-protein kinase (RIPK) 1 and 3. To define the role of IAPs in
myelopoiesis, we generated a mouse with cIAP1, cIAP2, and XIAP deleted in the myeloid
lineage. Loss of cIAPs and XIAP in the myeloid lineage caused overproduction of many
proinflammatory cytokines, resulting in granulocytosis and severe sterile inflammation.
In vitro differentiation of macrophages from bone marrow in the absence of cIAPs and
XIAP led to detectable levels of TNF and resulted in reduced numbers of mature macro-
phages. The cytokine production and consequent cell death causedby IAPdepletionwas
attenuatedby lossor inhibitionof TNForTNF receptor 1. The lossofRIPK1orRIPK3,but not theRIPK3substratemixed lineagekinase
domain-like protein, attenuated TNF secretion and thereby prevented apoptotic cell death and not necrosis. Our results demonstrate
that cIAPs and XIAP together restrain RIPK1- and RIPK3-dependent cytokine production in myeloid cells to critically regulate
myeloid homeostasis. (Blood. 2014;123(16):2562-2572)
Introduction
A well-characterized function of inhibitor of apoptosis proteins
(IAPs) is their ability to block cell death. XIAP binds to and inhibits
effector caspases and the initiator caspase, caspase-9, and is therefore
a direct apoptosis inhibitor.1 Unsurprisingly, compounds that mimic
natural inhibitors of IAPs, such as Smac/DIABLO, were developed
as antitumor agents. Unlike XIAP, cIAP1 and cIAP2 do not directly
inhibit caspases2 but instead promote prosurvival signaling from
tumor necrosis factor receptor (TNFR) 1 complex I and also limit
formation of the apoptosis-inducing TNFR1 complex II.3-5 Several
Smac mimetics have been developed, and pan-IAP inhibitors were
shown to kill tumor cells by causing cIAP1/2 degradation, leading to
spontaneous activation of nuclear factorkB and consequent autocrine/
paracrine tumor necrosis factor (TNF)/TNFR1-induced cell death
signaling.6-9
The observation that Smac mimetics trigger TNF production in
certain tumor cells suggests that IAPs regulate cytokines, and in
some cell types, this is critical for proper regulation of cell death.
Monocytes and macrophages treated with Smac mimetics die in
a TNF/TNFR1-dependent manner that requires receptor-interacting
serine/threonine-protein kinase (RIPK) 1 signaling.10,11 By contrast,
single loss of cIAPs or XIAP has been shown to reduce cytokine
production after stimulation of Nucleotide-binding and oligomeri-
zation domain 1 (NOD1), NOD2, Toll-like receptors (TLRs), or
TNF,12-16 contrary to observations made using Smac mimetics. To
add to the confusion,mutations inXIAPhave been found inX-linked
lymphoproliferative syndrome and in a case study of inﬂammatory
bowel disease symptoms,17,18 suggesting that inactivity or a lack of
XIAP triggers chronic inﬂammation in vivo.
Death domain–containing members of the TNFR superfamily
and pattern recognition receptor family members (TLR) can not only
induce caspase-dependent apoptosis but also trigger programmed
necrosis, also known as necroptosis, in certain contexts.19 Stimula-
tion of death receptors or TLRs normally triggers apoptosis, but
in the absence of caspase-8 function, this instead elicits RIPK3-
dependent necroptosis. RIPK3-dependent phosphorylation of mixed
lineage kinase domain-like protein (MLKL) and phosphoglycerate
mutase family member 5 (PGAM5) was reported to be required for
necroptosis induction, and although the subsequent molecular
necroptotic signaling events remain unclear, increased mitochon-
drial ﬁssion and reactive oxygen species production have been
implicated.20-22 Smac mimetic–mediated IAP depletion causes the
formation of a RIPK1, caspase-8, and Fas-Associated protein with
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Death Domain (FADD)-containing complex that has been named
the Ripoptosome1,23-26 and is thought to cause necroptotic cell
death. Moreover, recent evidence suggests that TNF production
triggered by loss of cIAPs or pharmacologic inhibition of caspases
is regulated by RIPK1, at least in L929 cells.2,27
We generated gene-targeted mice to determine the role of cIAPs
and XIAP in cytokine production in the myeloid lineage. We found
that cIAPs and XIAP together suppress the production of multiple
cytokines and chemokines, including TNF, thereby regulating the
homeostasis and function of mature myeloid cells. In contrast to
tumor cells, in which loss of cIAPs alone causes TNF production and
TNF/TNFR1-mediated cell killing, combined loss of XIAP and
cIAPs was required for TNF induction and TNF/TNFR1-mediated
killing of macrophages. TNF messenger RNA (mRNA) production
was dependent on RIPK1, and secretion of TNF was dependent on
RIPK3. These ﬁndings suggest that RIPK1 and RIPK3 regulate cyto-
kine production directly and this function resides upstream of, and
distinct from, the role of these 2 kinases in the induction of necroptosis.
Materials and methods
Mice
Mice were maintained in a conventional animal facility, and experiments
performed according to the guidelines of La Trobe University Ethics
committee (09-41B and 09-57B) and the Walter and Eliza Hall Institute of
Medical Research (WEHI) Animal Ethics Committee. loxP and FRT sites
were introduced into the adjacent cIap1 and cIap2 genes by sequential gene
targeting in C57BL/6-derived embryonic stem (ES) cells.3-5,28 Ubiquitous
inactivation of cIAP2 expression was achieved by Flpe transgene (B6;SJL-
Tg:F4[ACTFLPe]9205Dym/WEHI) (cIap1ﬂ/ﬂcIap22/2). These mice were
intercrossed with transgenic Cre mice, inserted by homologous recombina-
tion into the lysozyme M locus (LysM-Cre: B6.129; CB.20-Tg; F6[LysM-
Cre]/WEHI) mice,6-9,29 thus producing animals with myeloid cell–speciﬁc
inactivation of cIAP1 (cIap1ﬂﬂcIap22/2, LysMcre/1 5 c1LCc22/2). Animals
were further intercrossed with Xiap2/2mice (B6.129:F10-XIAPTm1/WEHI).
Ripk12/2,30 Ripk32/2,31 TNFR12/2, and TNFR22/2 mice were originally
generated on a 129/SV genetic background and backcrossed to C57Bl/6mice
for at least 8 generations. Tnf2/2 and Mlkl2/2 mice were generated on
a C57BL/6 background.32 Bone marrow reconstitutions of Ripk12/2 fetal
liver on the C57BL/6.129 background failed to produce.95% reconstitution
efﬁciency, resulting in the use of fetal livers from timed matings to produce
Ripk12/2 macrophages. Wild-type (WT), Ripk32/2, and Tnf2/2 mice were
injectedwithSmacmimetic (Abbott11) at 20mg/kg single dose or over 2weeks
(5days on/2days off), andcell typeswere assessed. cIap1lysCrecIAP22/2Xiap2/2
mice (c1LCc22/2X2/2) from 3 weeks of age were injected with anti-TNF
(MP6-XT22, 10 mg/kg) for 3 weeks, 3 times per week.
Flow cytometry
Flow cytometry was performed on a FacsCanto (BD Biosciences) with
FacsDiva software (BD Biosciences) or LSR1 with Cell Quest software (BD
Biosciences), and data processing performed using Weasel (WEHI). Single-
cell suspensions were prepared from spleens and bone marrow. Spleen cell
suspensionswere subjected to erythrocyte depletion using red blood cell lysis
buffer. Approximately 23 106 cells were stained, and antibodies and gating
strategies used are provided in supplemental Materials and methods (see the
Blood Web site). Dead cells were excluded from analysis by staining with
propidium iodide (PI; 2 mg/mL). In vitro cell survival assays were performed
as previously described.9-11
Compounds and antibodies
Smac mimetic compounds/pan-IAP inhibitors Compound A (Comp. A;
GT12911), cIAP1/cIAP2 speciﬁc inhibitor (TL32711), and Abbott11 were
synthesized by TetraLogic Pharmaceuticals. Other compounds used were
QVD-OPH (MP Biomedicals) and necrostatin-1 (Nec-1; Biomol). Rat anti-
mouse TNF (MP6-XT22) and isotype control (GL113) were purchased from
WEHI monoclonal laboratory.
Cell culture
Cell suspensions from bone marrow were cultured for 6 days in Dulbecco’s
modiﬁed Eagle medium1 10% fetal bovine serum (volume to volume ratio)
1 20% (volume to volume ratio) L929mouseﬁbroblast conditionedmedium.
The resulting bone marrow–derived macrophages (BMDMs) were then
replated at 1 3 106 cells per mL and assayed in the presence of L929 con-
ditioned medium. Peritoneal macrophages were obtained 4 days after
injection with 1% thioglycollate (weight to volume ratio), sorted for
Mac11Gr1– cells, and assayed for sensitivity to Smac mimetic–induced
cell killing. Fetal liver–derived macrophages (FLDMs) were obtained by
culturing fetal liver–derived cells from E14.5 fetuses in a manner similar
to the bone marrow–derived cells (as described previously).
Cytokine measurement
Enzyme-linked immunosorbent assays (ELISAs) for the measurement of the
concentrations of TNF, granulocyte colony-stimulating factor (G-CSF),
macrophage CSF (M-CSF), granulocyte macrophage CSF (GM-CSF), in-
terleukin (IL) 1b, and IL-6 were performed following the manufacturers’
instructions (R&D Research and eBioscience, respectively). The 23-plex
mouse cytokine assays (Bio-Rad) were performed following the manufac-
turer’s instructions and assayed on a Bio-Rad Bioplex machine.
Quantitative polymerase chain reaction (PCR)
Relative levels of target genes were determined using relative comparative
threshold cycle to assess TNF mRNA levels with b2-microglobulin as the
housekeeping gene using SYBR Green (Life Technologies). Primer
sequences are available upon request. Viia7 was used to perform quantitative
PCR (Life Technologies).
Histology
Organs were ﬁxed in 4% paraformaldehyde, parafﬁn embedded, and
sectioned for hematoxylin and eosin or subjected to heat-induced epitope
retrieval with citrate buffer, blocked in 3% goat serum, permeabilized with
0.3% Triton X-100, and stained with cleaved caspase-3 (Cell Signaling
Technology). Images were taken using a Wideﬁeld Leica DMI 6000 with
a digital color camera LeicaDFC420 orMirax slide scannerwith 3CCDcolor
camera, and processed using Panoramic Viewer.
Hematopoietic cell colony assays
Single-cell suspensions from bone marrow or spleens from newborn pups
(day 1-4) were resuspended in 0.3% (weight to volume ratio) agar and
Dulbecco’s modiﬁed Eagle medium 1 20% fetal bovine serum at
a concentration of 2.5 3 104 cells per plate. Cells were incubated with
10 ng/mL recombinant murine (rm) GM-CSF, rm M-CSF, or recombinant
humanG-CSFaloneor in combination, in addition to 25ng/mLrmIL-3, 2U/mL
erythropoietin, and 100 ng/mL rm stem cell factor for 7 days at 37°C. On day 7,
colonies were ﬁxed and stained for counting.
Blood cell analysis
Blood was collected from the retro-orbital plexus into tubes containing
potassium ethylenediaminetetraacetic acid (Sarstedt) and analyzed in an
Advia 2120 automated hematologic analyzer (Bayer).
Statistical analysis
Cytokine measurements were assessed individually by Student t tests
for single genotypes. Analysis of variance was performed followed by
Bonferroni posttests to compare individual genotypes or conditions.
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Results
Combined loss of XIAP and cIAPs in myeloid cells results
in inflammation
To determine the effects of selective loss of XIAP and cIAPs in the
myeloid lineage in vivo, we generated cIap1ﬂ/ﬂcIap2FRT/FRTXiap2/2
mice using a lysozyme M-promoter–driven Cre transgene12-16,29
and a ubiquitously expressed FLPe transgene.17,18,33 In these
cIap1lysCrecIAP22/2Xiap2/2 mice (c1LCc22/2X2/2), XIAP and
cIAP2 are deleted in all cell types, whereas cIAP1 is selectively
lost in the myeloid lineage: granulocytes, macrophages, and a minor
fraction of dendritic cells.19,34 Although c22/2X2/2mice are pheno-
typically normal, the c1LCc22/2X2/2 mutant mice were runted
comparedwith littermate controls and had a splayed gait and hunched
posture (Figure 1A-B).
Sera from 6- to 12-week-old c1LCc22/2X2/2, c1ﬂ/ﬂc22/2X2/2,
and WT mice were assayed for cytokines by ELISA or multiplex.
G-CSF,M-CSF, TNF, and IL-6 (measured by ELISA) were elevated
in c1LCc22/2X2/2 animals compared with WT controls (P , .01,
G-CSF, M-CSF, and TNF and P, .01, IL-6; Figure 1C). Of the 23
cytokines assayed in a multiplex format, 10, including IL-12p40,
Eotaxin, monocyte chemotactic protein 1 (MCP1), and regulated on
activation normal T expressed and secreted,were signiﬁcantly higher
in the c1LCc22/2X2/2 mice compared with the control animals
(supplemental Figure 1). Some cytokines and chemokines also
appeared to be abnormally elevated in the sera of c22/2X2/2 mice,
but the loss of all 3 IAPs caused the greatest increase in the levels of
cytokines and chemokines, including IL-1b, G-CSF, M-CSF, and
TNF. In contrast,mice deﬁcient in a single IAP,whether itwas cIAP1,
cIAP2, orXIAP, did not display abnormally increased levels of any of
the cytokines or chemokines tested (data not shown).
Deletion of cIAPs and XIAP causes granulocytosis
and splenomegaly
c1LCc22/2X2/2 mice presented with granulocytosis and spleno-
megaly, characterized by loss of splenic architecture (Figure 2A-C).
In addition to the altered spleen structure, signs of inﬂammationwere
observed in liver and lung (Figure 2C and supplemental Figure 2A).
The enlarged spleen was the result of an increase in cell numbers,
particularly Ly6G1 neutrophils (Figure 2D and supplemental
Figure 2). The femur and tibia of c1LCc22/2X2/2 mice were pale,
small, and brittle, and analysis of the cellular content showed a slight
increase in granulocytes, a decrease in F4/801 monocytes and
B2201 B cells, and a lack of erythroid cells (Ter1191) (Figure 2E).
c1LCc22/2X2/2 mice showed a decrease in resident F4/801Ly6Clo
monocytes and an increase in inﬂammatory F4/801Ly6Chi mono-
cytes in the bone marrow compared with WT and c1ﬂ/ﬂc22/2X2/2
mice. Skewing toward an inﬂammatory phenotype in c1LCc22/2X2/2
mice was further highlighted by increased numbers of F4/801
monocyte/macrophage subsets in the spleen, particularly the inﬂam-
matory subset (Figure 2F). Myeloid populations were sorted and
assessed for effective deletion of cIAP1 (supplemental Figure 2C).
cIAP1 was effectively deleted from granulocytes (Ly6G1 cells) but
not fromF4/801Ly6Clo cells, and the effectiveness of cIAP1 deletion
varied in c1LCc22/2X2/2 mice (supplemental Figure 2D). This
suggests that the variation in phenotype may be attributable to the
effectiveness of cIAP1 deletion by lysozyme M cre.
Combined loss of cIAPs and XIAP does not impair myeloid cell
differentiation but impairs macrophage survival
To determine the effect of abnormally high cytokine levels on myeloid
homeostasis, we examined the numbers of myeloid progenitors in the
bone marrow. c1LCc22/2X2/2mice had substantially reduced numbers
Figure 1. Specific combined loss of cIAPs and XIAP in the myeloid lineage results in chronic inflammation. (A) Image of a c1LCc22/2X2/2 mouse (deficient for cIAP1
only in myeloid cells and deficient for cIAP2 and XIAP in all tissues) and a littermate mouse. (B) Weights of c1LCc22/2X2/2, c1fl/flc22/2X2/2, and WT mice. (C) Levels of
G-CSF, M-CSF, TNF, and IL-6 in the sera of c1LCc22/2X2/2, c1fl/flc22/2X2/2, and WT mice. Each point represents an individual mouse. Mean 6 standard error of the mean
(SEM) are shown. **P , .01; *P , .05.
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Figure 2. Combined loss of cIAPs and XIAP in the myeloid lineage causes granulocytosis, splenomegaly, and extramedullary hematopoiesis. (A) The numbers of
neutrophils, monocytes, and total leukocytes per microliter of blood in c1LCc22/2X2/2, c1fl/flc22/2X2/2, and WT mice were determined by using an automated ADVIA blood
analyzer. (B) The ratios of the spleen to total body weight, as well as the spleen weights of 6- to 12-week-old c1LCc22/2X2/2 and control (WT, c1fl/flc22/2X2/2) mice were
determined by weighing the mice and their spleens. (C) Splenic architecture and liver histology of WT, c1fl/flc22/2X2/2, and c1LCc22/2X2/2mice. The bars represent 50 mm; 310,
numerical aperture (NA) 0.3 and 340, NA 0.6 magnification, respectively. (D) Total numbers of CD41 T cells, CD81 T cells, total B cells (B2201), granulocytes (Ly6G1), and
macrophages (F4/801) in spleens of 6- to 12-week-old c1LCc22/2X2/2 as well as control (WT, c1fl/flc22/2X2/2) mice were determined by counting total leukocytes in
these tissues and multiplying them with the percentages of these cell subsets that were determined by flow cytometric analysis. (E) The numbers of erythroid (TER1191),
B lymphoid (B2201), granulocytic (Ly6G1), and macrophage/monocyte (F4/801) cells in the bone marrow of c1LCc22/2X2/2 and control (WT, c1fl/flc22/2X2/2) mice were determined
as in panel C. (F) The numbers of F4/801 cells were further assessed as resident (Ly6Clo) or inflammatory (Ly6Chi) in the bone marrow and spleen of c1LCc22/2X2/2,
c1fl/flc22/2X2/2, and/or WT mice. In panels B-F, each data point represents an individual mouse (6-12 weeks old); the mean 6 SEM are also shown. **P , .01; *P , .05.
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of common myeloid and megakaryocyte erythroid progenitors, but not
granulocyte macrophage progenitors, in their bone marrow compared
with littermate controls (Figure 3A and supplemental Figure 3).
To determine whether the loss of cIAP2 and XIAP in all tissues
contributed to the severe pathology of the c1LCc22/2X2/2 mice,
WT (C57BL/6-Ly5.1) mice were lethally irradiated and reconstituted
Figure 3. Combined loss of cIAPs and XIAP does not impair myeloid cell differentiation but impairs survival of cells in macrophage colonies. (A) Representative
fluorescence-activated cell sorter plots with percentages of surface marker staining to identify myeloid progenitors in the bone marrow of WT, c1fl/flc22/2X2/2, and c1LCc22/2X2/2
mice. Cells were gated for Sca1–c-kit1 and further gated for FcgRcII/III and CD34 (CMP, common myeloid progenitor; GMP, granulocyte macrophage progenitor; MEP,
megakaryocyte erythrocyte progenitor). (B) Spleen cells from newborn WT, c1fl/flc22/2X2/2, and c1LCc22/2X2/2mice were plated in agar with either GM-CSF, Multi-CSF (GM-, G-,
M-CSF), or stem cell factor (SCF) 1 IL-3 1 Epo, and the numbers and morphologies of the colonies (Eo, eosinophil; G, granulocytes; GM, granulocyte-macrophage; M,
macrophage; Meg, megakaryocyte) determined after 7 days. N5 3 biological replicates. (C) BMDMs and peritoneal macrophages were treated with the indicated concentrations of
the Smac mimetic Comp. A and assayed 24 hours for cell death by flow cytometry. (D) BMDMs from mice of the indicated genotypes were either left untreated (-) or treated with
Comp. A (500 nM, 24 hours; 1). The percentages of dead cells were determined by flow cytometric analysis after staining with PI. N 5 3 experiments with BMDMs from individual
mice. (E) BMDMs from mice of the indicated genotypes were left untreated (open bars) or treated for 24 hours with either 500 nM Comp. A, a Smac mimetic that inhibits all of
cIAP1, cIAP2, and XIAP, or with 500 nM of a Smac mimetic that only inhibits cIAP1 and cIAP2. The percentages of dead cells were determined by staining with PI followed by flow
cytometric analysis. N 5 3 experiments with BMDMs from individual mice of the genotypes indicated. Mean 6 SEM are shown. **P , .01; *P , .05.
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with bonemarrow fromWTor c1LCc22/2X2/2mice (both on aC57BL/
6-Ly5.2 background). Mice reconstituted with a c1LCc22/2X2/2
hematopoietic system consistently showed the pathology seen in
c1LCc22/2X2/2 mice suggesting that the pathology is attributable
to a hematopoietic cell intrinsic defect (supplemental Figure 3).
To examine whether the potential of myeloid progenitors was
altered in c1LCc22/2X2/2 mice, we performed colony assays. In
response to several cytokines, including G-CSF and Multi-CSF,
spleen cells from c1LCc22/2X2/2 mice produced lower numbers of
macrophage colonies compared with control (WT and c22/2X2/2
cells), whereas bone marrow cells were able to produce normal
numbers of macrophage colonies (Figure 3B, P, .05; supplemental
Figure 3). However, macrophage colonies formed from both spleen
and bone marrow cells comprised dead or dying cells (data not
shown), indicating a defect in macrophage survival. Consistent with
the abnormal death of macrophages in colony assays, it proved
difﬁcult to generate BMDMs from c1LCc22/2X2/2 mice. Further-
more, TNFwas readily detectable in the supernatants of c1LCc22/2X2/2
bone marrow cells cultured for 6 days in M-CSF but not in those
from their WT or c1ﬂ/ﬂc22/2X2/2 counterparts (data not shown).
Collectively, this demonstrates that combined loss of XIAP and
cIAPs in the myeloid lineage affects myeloid cell homeostasis
requiring extramedullary hematopoiesis. These results demon-
strate that loss of cIAP1, cIAP2, and XIAP causes increased death
of myeloid cells that may contribute to the chronic inﬂammation
and granulocytosis that develop in the c1LCc22/2X2/2 mice.
Loss of XIAP and cIAPs kills macrophages by TNF production
and activation of TNFR1-mediated cell death
BMDMs derived from c1LCc22/2X2/2 mice were selected for
incomplete deletion of cIAP1, consistent with the notion that
complete loss of cIAP1, cIAP2, and XIAP kills these cells.
Therefore, to further explore the impact of the combined loss of
cIAPs and XIAP, we used the bivalent, pan-IAP inhibitory Smac
mimetic Comp. A. Treatment with Comp. A efﬁciently killed
BMDMs and freshly isolated peritoneal macrophages from WT
mice, as assessed by ﬂow cytometric analysis of PI incorporation
(Figure 3C). Consistent with previously published data,10,20-22
treatment with TNF neutralizing antibodies (MP6-XT22) or genetic
loss of TNF and TNFR1, but not loss of TNFR2, rendered BMDMs
resistant to Smac mimetic–induced killing (Figure 3D, P, .001).
However, in contrast to previously published data, we found that the
killing of BMDMs required the loss or inhibition of XIAP in addition to
blockade or loss of cIAP1 and cIAP2 because only XIAP-deﬁcient, but
notWT, BMDMswere killed by the cIAP1-plus-cIAP2 selective Smac
mimetic TL32711 (P, .05, Figure 3E). In addition, althoughwe found
that all (27/27) c1LCc22/2X2/2 mice displayed runting, hunched
posture and a splayed gait, only a fraction of the cIap1LCcIap22/2
(4/19; c1LCc22/2) mice exhibited similar pathology (supplemental
Table 1). Interestingly, abnormally elevated levels of cytokines and
chemokines were found in sera from c1LCc22/2 animals with physical
attributes similar to c1LCc22/2X2/2 mice (data not shown). This
suggests that although combined loss of cIAP1 plus cIAP2 inmyeloid
cells is sufﬁcient to cause chronic inﬂammation, complete loss of all 3
IAPs in the myeloid lineage is required for severe pathology.
Loss of XIAP and cIAPs triggers production of certain cytokines
and chemokines independent of TNF and prior to induction of
cell death
To investigate whether the increase in cytokines and chemokines
triggered by loss or blockade of cIAPs and XIAP might be a
secondary consequence of the increased production of TNF, we
treated BMDMs from WT and Tnf2/2 mice with Comp. A for
24 hours. With the exception of MCP1, production of several
cytokine/chemokines was dampened compared with WT macro-
phages (Figure 4A). These results show that Smacmimetic treatment is
sufﬁcient to directly induce production of several inﬂammatory cyto-
kines, but that autocrine TNF/TNFR1 signaling is necessary for
maximal production of most of these cytokines.
To determine which cytokines and chemokines were induced
independently of cell death, we measured both cell death and cyto-
kine release over time. Lactate dehydrogenase (LDH) release was
only detectable 4.5 hours after the presence of TNF could be detected
in supernatants or cell lysates (Figure 4B-C). Interestingly, LDH
release also increased in Tnf2/2BMDMs treated with Smacmimetic
at 8 hours, suggesting that LDH release may not fully correlate
with macrophage cell death because Tnf2/2 BMDMs do not die in
response to Smac mimetic treatment. In WT BMDMs, poly(ADP-
Ribose) polymerase (PARP) cleavage was detectable within 6 hours
of Smacmimetic treatment, and the presence of Highmobility group
protein 1 or cyclophilin A, known damage-associated molecular
pattern molecules, could be detected by 4.5-6 hours but was not
limited to WT BMDMs (data not shown). Conversely, secretion of
MCP1 and macrophage-inﬂammatory proteins 1a and 1b could
already be detected within 1.5 hours of Smac mimetic treatment,
whereas IL-10 and Keratinocyte-derived chemokine were only
observed at 4.5 hours (Figure 4D). These results show that Smac
mimetic treatment induces production of diverse inﬂammatory
cytokines by macrophages prior to cell death.
Loss of RIPK1 or RIPK3 attenuates Smac mimetic–induced
macrophage killing by limiting TNF production
Because IAPs have been shown to inhibit both caspase-dependent
apoptosis and RIPK3-mediated necroptosis,25,35,36 we examined the
mechanism by which Smac mimetics kill BMDMs. Although the
broad-spectrum caspase inhibitor QVD-OPH effectively inhibited
Smac mimetic–induced caspase-3 activation and PARP cleavage in
BMDMs (data not shown), it did not prevent killing; instead, it
increased the percentage of dead cells (Figure 5A). In most cellular
systems, the RIPK1 inhibitor Nec-1 only blocks death receptor–
induced (eg, TNFR1) cell death when it is combined with caspase
inhibitors.22,24,35,37,38 It was therefore surprising that Nec-1 alone
completelypreventedSmacmimetic killingofBMDMsover a rangeof
5-50mM(Figure 5Aanddatanot shown). Toensure speciﬁcity ofNec-
1,we treatedRipk11/1 andRipk12/2FLDMswithComp.A and found
no increase in LDH release in RIPK1-deﬁcient macrophages compared
with WT or increase in percentage of dead cells as measured by PI
uptake (Figure 5A and data not shown). These data were consistent
with previous reports of Smac mimetics inducing necroptotic cell
death,10,11 but inconsistent with our observations that cleaved caspase-3
is detectable in inﬂamed lung and liver histology of c1LCc22/2X2/2
mice, caspase-3 activity is induced in WT and Ripk32/2 BMDMs
treated with Smac mimetic, and PARP cleavage is detected early
(6 hours post Comp.A) (Figure 5B-C and data not shown; supplemental
Figure 5).
To determinewhether Smacmimetic induced a solely necroptotic
death inmacrophages, we examinedBMDMsderived fromRipk32/2
and Mlkl2/2 mice. Smac mimetic–induced killing of BMDMs was
inhibited by loss of RIPK3; however, it was only partially limited by
MLKL loss. Furthermore, Comp. A–induced death of MLKL-
deﬁcient BMDMs was further reduced by Nec-1 (Figure 5A). These
results strongly suggested that the kinase activity of RIPK1 has a
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function in addition to activating an RIPK3/MLKL necroptosis-
inducingcomplex.We thereforeexaminedTNFproduction inRipk32/2
and Mlkl2/2 mice. Surprisingly, Smac mimetic–induced TNF pro-
duction was markedly reduced in both RIPK1- and RIPK3-deﬁcient
BMDMs, whereasMlkl2/2 BMDMs produced similar levels of TNF
as WT cells. Cotreatment with Nec-1 and Comp. A blocked Smac
mimetic–induced TNF production in WT macrophages and even
those lacking RIPK3 orMLKL, suggesting that the kinase activity
of RIPK1 is important for TNF production (Figure 5D).
Investigations into TNF induction in WT BMDMs revealed that
TNFmRNA levels increased approximately fourfold within 6 hours
of Smac mimetic treatment, whereas Nec-1 treatment prevented
Smac mimetic–induced TNF mRNA production (Figure 5E). Sur-
prisingly, loss of RIPK3, which signiﬁcantly limited Comp.
A–induced TNF protein production and secretion (Figure 5F), did
not reduce induction of TNF mRNA. On the contrary, TNF mRNA
levels were approximately threefold higher in Ripk32/2 BMDMs
compared with WT BMDMs at 4.5 and 6 hours of Smac mimetic
treatment (Figure 5E). The addition of Nec-1 was able to abrogate
this increase in TNF mRNA in the RIPK3-deﬁcient BMDMs
(Figure 5E). Addition of Nec-1 and loss of RIPK3 similarly affected
Smac mimetic–induced production of several other cytokines (sup-
plemental Figure 4).
These observations indicate that RIPK1 and RIPK3, but not
MLKL, exert distinct functions in the stimulation of cytokine
production that is triggered by the loss or blockade of cIAP1/2 plus
XIAP. Furthermore, the data reveal that the roles of RIPK1 and
RIPK3 in cytokine production and cell death are distinct processes.
Smac mimetic treatment causes an increase in cytokine levels
in vivo, and this can be attenuated by loss of TNF or RIPK3
To investigate whether administration of Smac mimetic in vivo
recapitulates the c1LCc22/2X2/2 inﬂammatory phenotype and how
IAPs repress cytokine production, we injected WT, Tnf2/2, and
Ripk32/2 mice intraperitoneally with 20 mg/kg of the monovalent
Figure 4. Smac mimetics stimulate cytokine pro-
duction in macrophages prior to initiation of cell
death. (A) WT or Tnf2/2 BMDMs were either left
untreated or stimulated in culture for 24 hours with the
Smac mimetic Comp. A (500 nM). The concentrations
of the cytokines indicated were measured by multiplex
bead assays. N 5 4 experiments with BMDMs from
individual WT mice; N 5 2 experiments with BMDMs of
individual Tnf2/2 mice. (B) LDH release was measured
in supernatants of WT and Tnf2/2 BMDMs after
treatment with 500 nM Comp. A over 0-8 hours. N . 6
experiments with BMDMs from individual WT mice. (C)
WT BMDMs were stimulated in culture for the times
indicated with 500 nM Comp. A, and TNF was measured
in cell lysates and supernatants. N . 3 experiments with
BMDMs from individual WT mice. (D) WT BMDMs were
stimulated in culture for the times indicated with 500 nM
Comp. A. Culture supernatants were assayed for various
cytokines by multiplex bead assay. N 5 3 experiments
with BMDMs from individual WT mice. Mean 6 SEM are
shown. **P , .01; *P , .05.
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Figure 5. Apoptosis and not necroptosis is triggered by combined loss of cIAPs and XIAP and is dependent on RIPK1, which is critical for tnf transcription, and
RIPK3, which is required for TNF secretion. (A) BMDMs of the genotypes indicated were treated for 24 hours with any of the following compounds alone or in combination:
the RIPK1 inhibitor Nec-1 (50 mM), the broad-spectrum caspase inhibitor QVD-OPH (10 mM), and the Smac mimetic Comp. A (500 nM). The percentages of dead cells were
determined by staining with PI followed by flow cytometric analysis. FLDMs from Ripk11/1 and Ripk12/2 embyros were similarly treated with the exception of Nec-1 (5 mM).
LDH release was measured in supernatants 24 hours after treatment. (B) Cleaved caspase-3 detected in lung histology of c1LCc22/2X2/2 mice but not littermate controls
(c1wt/flc21/2X2/2, c1fl/flc22/2X2/2). The bars represent 50 mm; 320 magnification, NA 0.8. (C) WT and Ripk32/2 BMDMs treated with Smac mimetic (Comp. A, 500 nM) for
0-6 hours and lysates assayed for caspase-3 activity. (D) BMDMs of the genotypes indicated were treated with Comp. A (500 nM), anti-TNF (0.1 mg/ml), Nec-1 (5 or 50 mM),
and/or QVD-OPH (10 mM) for 24 hours. The levels of TNF in culture supernatants were measured by ELISA. (E) BMDMs of the genotypes indicated were treated for the times
indicated with 500 nM Comp. A, either alone or together with 50 mM Nec-1 (as indicated). The levels of TNF mRNA were determined by relative quantitative PCR and
expressed relative to WT BMDMs without treatment with Comp. A treatment. (F) WT, Ripk32/2, and Tnf2/2 BMDMs treated with Smac mimetic (Comp. A, 500 nM) for 0-7.5
hours. TNF in cell lysate (left) and supernatant (right) was assessed by ELISA, and the latter normalized to amount of protein. In panels A-F, N $ 3 experiments with BMDMs
or FLDMs from individual mice or embyros of the genotypes indicated. Mean 6 SEM are shown. ***P , .001; **P , .01; *P , .05.
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pan-IAPSmacmimetic compoundAbbott11; this dosewaspreviously
shown to inhibit tumor growth in a murine xenograft model.39 In WT
mice, the levels of IL-12, G-CSF, MCP1, IL-6, and regulated on
activation normal T expressed and secreted all rose within 5 hours
(Figure 6A). In agreement with our in vitro studies (Figure 4A and
supplemental Figure 4), we found that the induction of these cytokines
was greatly attenuated in Ripk32/2mice and almost absent in Tnf2/2
mice (Figure 6A). The detection of fewer cytokines in the serum
compared with in vitro (Figure 4A) is likely attributable to the
effectiveness of a monovalent vs bivalent pan-IAP Smac mimetic
compound to inhibit cIAPs and XIAP.
To determine whether long-term exposure to Smac mimetics
could induce pathological abnormalities similar to those seen in
c1LCc22/2X2/2 mice, we injected mice intraperitoneally with
Abbott11 (20 mg/kg body weight) for 2 weeks, 5 days on/2 days off.
Despite the reduced levels of cytokines detected in the serumofTnf2/2
mice, an increase in spleen size was still seen and was caused by
increased splenic granulocytes (Ly6G1) andmacrophages (F4/801). In
contrast, increased splenic cell numbers and spleen size were not
observed in Ripk32/2 mice injected with Abbott11 (Figure 6B-C
and data not shown). To determine if TNF/TNFR1-mediated cell
death of macrophages in the c1LCc22/2X2/2mice was the cause of
the disrupted myelopoiesis, we intraperitoneally injected anti-TNF
(MP6-XT22, 10mg/kg) for 3weeks, 3 times perweek from 3weeks
of age.After anti-TNF injection, c1LCc22/2X2/2mice had a decreased
number of granulocytes and inﬂammatory monocytes compared with
untreated c1LCc22/2X2/2 mice (Figure 6D). This suggests that
production of TNF is a major player in disrupting myelopoeisis, but
the splenomegaly seen in c1LCc22/2X2/2mice may be attributable to
additional cytokines either induced by TNF and cell death or directly
by the loss of IAPs in the myeloid compartment.
Discussion
Our study demonstrates that cIAPs and XIAP cooperate in vivo to
limit production of proinﬂammatory cytokines by myeloid cells and
thereby prevent death of macrophages. Although some c1LCc22/2
mice presented with a phenotype comparable to that of c1LCc22/2X2/2
mice, many were indistinguishable from littermate WT controls
based onweight and stature. The combined loss of XIAP, cIAP1, and
cIAP2 in the myeloid lineage was required to produce high levels of
inﬂammation, accompanied by granulocytosis and extramedullary
hematopoiesis. This suggests either that IAPs have overlapping
physiological roles or that they regulate the same pathway(s), but at
distinct steps of myeloid differentiation. In addition, it suggests that
the most inﬂuential physiological role that IAPs play is in regulating
cytokine production.
The bivalent pan-IAP Smac mimetic compounds BV6 and SM-
164 were shown to efﬁciently kill human monocytes and BMDMs,
respectively.10,11 The BV6-induced death of human monocytes was
associatedwith loss ofXIAP and could not be entirely blocked by the
RIPK1 inhibitor Nec-1. In this way, BV6-treated human monocytes
resembled c1LCc22/2X2/2BMDMs, which were sensitive to killing
by TNF alone, a death process that could only be partially inhibited
by Nec-1 (data not shown). Similar to others,10 we found that
Smac mimetic–induced killing of macrophages was dependent on
autocrine TNF/TNFR1 signaling but determined that this signaling
led to an apoptotic, and not necrotic, cell death. Blocking TNF in
vivo decreased granulocyte numbers and inﬂammatory monocytes
in c1LCc22/2X2/2 mice suggesting that TNF and the cell death in
IAP-depleted myeloid cells is one of the main components to
disrupting myeloid homeostasis. The complex phenotype seen by
genetic deletion of cIAPs and XIAP may be attributable to the
combination of apoptosis and subsequent necrosis attributable to
damage-associated molecular pattern molecules and proinﬂamma-
tory cytokines other than TNF (supplemental Figure 6).
Injection of the monovalent pan-IAP blocking Smac mimetic
compoundAbbott1139 was well tolerated in themice at 20mg/kg for
single or multiple injections. An increase in the concentration of
proinﬂammatory cytokines ensued 5 hours post Smac mimetic
injection, but after 24 hours, the levels of cytokines returned to
baseline (data not shown). In addition, examination of myelopoi-
esis following repeated injections of Abbott11 revealed splenomegaly
(Figure 6B) and abnormalities in hematopoiesis, suggesting that
Figure 6. RIPK3 is essential for the cytokine
production and ensuing granulocytosis that are
caused by the combined loss of cIAPs and XIAP.
(A) WT mice were either left untreated (-) or injected
intraperitoneally (1) with the Smac mimetic compound
Abbott11 (20 mg/kg body weight). After 5 hours, the
levels of the cytokines and chemokines indicated were
measured by multiplex. (B-C) Mice of the genotypes
indicated were either left untreated (-) or injected
intraperitoneally (1) with the Smac mimetic compound
Abbott11 (20 mg/kg body weight) for 2 weeks (daily for
5 days, then 2 days of rest). (B) The ratios of the spleen
weight to total body weight of the mice after injection of
Abbott11 were compared with the ratios from untreated
control animals. (C) Increased numbers of granulocytes
(Ly6G1) and macrophages (F4/801) were found in
spleens of WT and Tnf2/2 mice injected with Abbott11
but not in Abbott11-injected Ripk32 /2mice. (D)
c1LCc22 /2X2/2 mice were injected with anti-TNF
(MP6-XT22, 10 mg/kg) for 3 weeks and assessed for
changes in granulocyte (Ly6G1) and monocyte
(F4/801Ly6Clo and F4/801Ly6Chi) populations in the
peripheral blood. Each point represents an individ-
ual mouse. Mean 6 SEM are shown. ***P , .001;
**P , .01; *P , .05.
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long-term treatment of a pan-IAP Smac mimetic compound may
lead to inﬂammatory consequences akin to that observed in c1LCc22/2
X2/2mice. The IAP selective Smacmimetic TL32711, which targets
cIAP1/2, only caused death in BMDMs deﬁcient in XIAP, leaving
WT BMDMs viable. Therefore, this suggests that a selective Smac
mimetic compoundwould be better tolerated, but it remains to be seen
if these compounds will retain signiﬁcant antitumor activity in vivo.
Our results show that combined loss of cIAP1/2 andXIAP causes
an abnormal increase in cytokine/chemokine production and not all
the effects seen in vivo can be rescued by loss of TNF (Figure 6). Our
ﬁndings agree with Kearney et al16 that cIAPs and XIAP directly
regulate other cytokines in addition to TNF. We recently found that
in lipopolysaccharide-primed macrophages, cIAP1/2 and XIAP
inhibit NOD-like receptor family, pyrin domain containing
3-caspase-1 inﬂammasome and caspase-8 activation of IL-1b.40 In
contrast to the essential role of RIPK1 kinase activity for TNF
production upon IAP removal, lipopolysaccharide and Smac
mimetic–induced activation of IL-1b was not blocked by Nec-1 or
TNF deﬁciency.40 IL-1bwas detected in the sera of c1LCc22/2X2/2
mice and supernatants of Smac mimetic–treated WT BMDMs, but
this appears to be a consequence of TNF production and/or macro-
phage cell death because Smac mimetic–induced IL-1b secretion was
severely reduced from TNF-deﬁcient macrophages.
Our data support the model whereby RIPK1 and RIPK3 can
facilitate the production of multiple cytokines, independent of their
role in necroptosis. This is further emphasized by the observation that
upon Smac mimetic treatment, MLKL-deﬁcient BMDMs upregu-
lated TNF comparable to WT BMDMs (Figure 5D). This alternative
role ofRIPK1andRIPK3maybe critical for amplifying thenecroptotic
pathway. Therefore, the ability of genetic loss of RIPK1 or RIPK3 to
prevent the embryonic lethality and chronic inﬂammation caused by
systemic or tissue selective deletion of FADD or caspase-841-43 might
in part be attributable to loss of a cytokine signaling ampliﬁcation loop
that depends on the RIPKs rather than solely being a consequence of
a block in necroptotic signaling.
The survival defect of cIAP- and XIAP-deﬁcient macrophages,
production of cytokines and the disruption in myeloid homeostasis
caused by loss of cIAPs and XIAP, is reminiscent of the consequences
of caspase-8 or cellular FLICE-inhibitory protein (cFLIP) loss in the
myeloid lineage. Tissue-speciﬁc loss of either caspase-8 or cFLIP in
the myeloid compartment (caspase-8LC; cFLIPLC) caused impaired
macrophage maturation44-46 and excess granulocytosis in cFLIPLC
mice.45 Moreover, cytokines associated with myeloid differentiation,
such as G-CSF, GM-CSF, and M-CSF, were elevated in the cFLIPLC
mice45 similar to the c1LCc22/2X2/2mice. Although excess levels of
cytokines and chemokines, such as G-CSF, GM-CSF, M-CSF, or
TNF, were not reported in the studies of caspase-8LC mice, treatment
with the pan-caspase inhibitor zVAD-fmk caused excess TNF
production in L929 cells and subsequent cell death,27 suggesting that
loss or inhibition of caspase-8 can cause production of cytokines in
certain cell types. Loss of RIPK3 rescued the ability of caspase-
8–deﬁcient myeloid progenitors to differentiate into macrophages,37
and in our experiments, loss of RIPK3 attenuated cytokine production
and exacerbated hematopoiesis caused upon Smac mimetic
treatment in vivo. Interestingly, a cytosolic complex consisting of
caspase-8, FADD, FLIP, and RIPK1 was found in U937 cells driven
to differentiate byM-CSF, and in these cells, cleavage of RIPK1 and
FLIP by caspase-8 reduced nuclear factor kB signaling.46 Collec-
tively, these and our results suggest that cIAPs and XIAP negatively
regulate the formation of the signaling complex that contains
caspase-8, FADD, FLIP, RIPK1, and possibly RIPK3. This complex
then signals to regulate cytokine/chemokine production in macro-
phage differentiation. Thus, in X-linked lymphoproliferative
syndrome17,47 or where cIAPs are degraded because of extracellular
signals,48-50 IAPs regulate cytokine production through a RIPK1/
RIPK3-dependent manner.
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